4//SEC Filing
Oh Chad 4
Accession 0001104659-23-083567
CIK 0001837607other
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 9:08 PM ET
Size
12.3 KB
Accession
0001104659-23-083567
Insider Transaction Report
Form 4
Oh Chad
Chief Medical Officer
Transactions
- Award
Restricted Stock Units
2023-07-21+100,428→ 100,428 total→ Common Stock (100,428 underlying) - Award
Stock Option
2023-07-21+145,588→ 145,588 totalExercise: $10.00Exp: 2031-08-23→ Common Stock (145,588 underlying) - Award
Stock Option
2023-07-21+115,151→ 115,151 totalExercise: $10.00Exp: 2032-03-09→ Common Stock (115,151 underlying)
Footnotes (6)
- [F1]On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.
- [F2]At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.
- [F3]Represents an award of stock options on August 23, 2021, which vests in four yearly installments from May 31, 2021, subject to the reporting person's continued service through the applicable vesting date.
- [F4]Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.
- [F5]At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.
- [F6]Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date.
Documents
Issuer
AEON Biopharma, Inc.
CIK 0001837607
Entity typeother
Related Parties
1- filerCIK 0001882166
Filing Metadata
- Form type
- 4
- Filed
- Jul 23, 8:00 PM ET
- Accepted
- Jul 24, 9:08 PM ET
- Size
- 12.3 KB